Letuan Phan

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma

Nadine Benhamouda, Ikuan Sam, Nicolas Epaillard et al. · Clinical Cancer Research · 2022 · 35 citations

Medicine, Immunology, Oncology +17

Preexisting autoantibodies as predictor of immune-related adverse events for advanced solid tumors treated with immune checkpoint inhibitors.

Arthur Daban, Cecile Gonnin, Yann Vano et al. · Journal of Clinical Oncology · 2022 · 24 citations

Life Sciences, Immunology, Oncology +17

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer

Stéphane Oudard, Raffaele Ratta, Éric Voog et al. · JAMA Oncology · 2023 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The <scp>CABIR</scp> study

Yann Vano, Letuan Phan, Gwénaëlle Gravis et al. · International Journal of Cancer · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +14